The US Food and Drug Administration approved the pill, which aims to increase the woman’s desire for sex – controversial decision, taken after a long lobbying campaign by the makers of the pink pill.
The Agency had an unusual number of restrictions on who can be prescribed this medication to minimize the risk of side effects.
The pill will be sold in the US under the name Adi. The Agency shall require the manufacturer of Adi – Sprout Pharmaceuticals specifically trained doctors and pharmacists who are involved in prescribing the medicine. Only trained doctors will have the right to prescribe the pill. Another task for doctors and pharmacists is to monitor for adverse effects among women who use it.
The main warning to women is to never consume alcohol while taking the drug and highlights the danger of sudden weakness that could be dangerous while driving.
Critics say the drug should not be approved because of the many side effects. But FDA has taken this decision because there is no other drug that helps women with severe lack of sexual desire, called hypoactive sexual desire.
The agency rejected the drug twice in the past, then the pharmaceutical company Sprout Pharmaceuticals purchased the rights to manufacture the drug from another pharmaceutical company – Boehringer Ingelheim. The main argument of the manufacturer, this kind of pill should be on the market is that men have more choices of drugs for sexual dysfunction, unlike women who have no alternative.
Adi act differently from drugs intended for the treatment of male sexual dysfunction. “The women’s Viagra” affect serotonin, it plays an important role in regulating aggression, body temperature, mood, sleep, vomiting, bleeding, sexuality and appetite. Affecting serotonin results in increased sexual desire in women.